Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | GMNN | O75496 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29193534 | 0.86 | MEN1 (0.67) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22116167 | 0.85 | CYP1A2 (0.82) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL12137165 | 0.85 | LMNA (0.64) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL9465312 | 0.83 | LMNA (0.67) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| Bromide SCHEMBL6143111 | 0.83 | LMNA (0.62) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL26640789 | 0.83 | CYP1A2 (0.69) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL2517754 | 0.83 | CYP1A2 (0.69) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| Butyryl-Carnitine SCHEMBL12137158 | 0.83 | CYP1A2 (0.79) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| Butyryl-Carnitine SCHEMBL12283483 | 0.83 | CYP1A2 (0.79) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22116165 | 0.82 | CYP1A2 (0.77) | CYP1A2MEN1KMT2AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-02-04 | — | — | US | disclosed |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | disclosed |
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-18 | — | — | US | disclosed |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | CYP1A2 694/4885MEN1 4750/4885KMT2A 2922/4885 |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | CYP1A2 676/4885MEN1 4759/4885KMT2A 2902/4885 |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | CYP1A2 676/4885MEN1 4759/4885KMT2A 2902/4885 |
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | CYP1A2 694/4885MEN1 4750/4885KMT2A 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.